


Scientific Program

Sunday 2 December, 2012

10:00 – 12:00	Parkside G04		
	PGx: new research interests and directions workshop		
14:30 – 16:30 Chairs	Parkside 110A	Parkside G04	Parkside 110B
	ASCEPT-APSA Careers workshop Careers in the pharmaceutical industry	ASCEPT-APSA Clinical Pharmacology workshop	ASCEPT-APSA Education Forum workshop
	Dr Barbara Kemp-Harper, Ms Claire Johnston, Ms Alice Kane	Introduction to TDM/TCI Dr Matt Doogue	Introduction and scene setting; TEQSA; Standards Panel and TLOs Prof Ieva Stupans, University of New England
	Finding your way in the Pharmaceutical Industry Dr Annette Gross, GlaxoSmithKline R&D It's a long way from rats and lab coats Dr Richard Booth, iNOVA Pharmaceuticals What I wish I knew about clinical trials roles and networking when I was sitting where you are today! Dr Craig Rayner, Roche How to locate and maximise your success in finding your ideal job Dr Amanda Reid, Daryl Alexander & Associates	Measuring drug concentrations, analytical methods and issues Dr Andrew Rowland Digoxin, a classic Prof Ray Morris The perhexiline story Prof John Horowitz	Mapping assessment to TLOs for pharmacy Prof Ieva Stupans, University of New England What is the relevance of TLOs for the teaching of pharmacology? Dr Liz Davis, Monash University and Dr Tina Hinton, The University of Sydney
17:00 – 18:00	Parkside Auditorium		
	Welcome to country Opening session and plenary 1 Prof David Le Couteur, ASCEPT President Prof Andrew McLachlan, APSA President Emeritus Prof Kim Oates AM, The University of Sydney		
18:00 – 19:30	Welcome Reception Parkside Foyer, Level 1		

Monday 3 December, 2012

08:00 – 09:00	Parkside Foyer, Level 1			
	Poster presentations			
	 SPONSORED BY			
09:00 – 10:00	Parkside Auditorium			
	Plenary 2: British Pharmacological Society lecture Proton pump inhibitors - robust evidence of public health hazard, or just plain confounding? - 101 Dr Yoon Loke, The University of East Anglia, UK			
10:00 – 10:30	Morning tea			
10:30 – 12:30 Chairs	Parkside Auditorium	Parkside 110A	Parkside 110B	Parkside G04
	Symposium 1: Drug transporters in clinical pharmacokinetics and drug-drug interactions	Symposium 2: The yin and yang of novel receptor drug discovery paradigms	Symposium 3: Emerging trends in dose individualisation in clinical practice	Symposium 4: The patient journey
	Dr Joseph Nicolazzo	Dr Meritxell Canals Buj	A/Prof Ross Norris A/Prof Betty Sallustio	Prof Ines Krass
	Transporter-based drug-drug interactions – principles and examples - 102 Prof Jashvant Unadkat, University of Washington, USA Role of organic cation transporters in mediating oral drug absorption - 103 Dr Dhiren Thakker, University of North Carolina, USA Role of transporters in mediating hepatobiliary clearance of drugs - 104 Prof Kim Brouwer, University of North Carolina, USA Impact of BBB Transporters on Delivery and Efficacy of Molecularly-Targeted Agents in Brain Tumors - 105 Prof William Elmquist, University of Minnesota, USA	Inflammation resolution mediators in tumour growth and metastasis: good, bad and indifferent - 106 Prof Alastair Stewart, The University of Melbourne Exploring allosteric modulation and ligand-directed stimulus bias at the glucagon-like peptide-1 receptor - 107 Denise Wooten, Monash University Physiological correlates of biased receptor signalling: relevance to opioid drug action in health and disease - 108 Dr Laura Bohn, The Scripps Research Institute, Florida, USA Revealing the potential of GPCR bias signalling - 109 Prof Andrew Tobin, University of Leicester, UK	Non-parametric population PK models and their use in individual patient care - 110 A/Prof Michael Neely, University of Southern California, USA Emerging trends in dose individualisation in clinical practice - 111 A/Prof Jennifer Martin, The University of Queensland Pharmacogenomics in dose individualisation - 112 Prof Elizabeth Phillips, Institute for Immunology & Infectious Diseases Dose individualisation of Dabigatrin - 113 Dr Paul Chin, University of Otago, NZ	The patient journey towards the end of life-patient and family accounts of patient safety - 114 Ms Aileen Collier, Centre for Health Communication, University of Technology Sydney Towards a medicinewise Australia: the NPS approach to improving health literacy - 115 Ms Karen Kaye, NPS Medicinewise





Monday 3 December, 2012 cont.

12:30 – 13:30	Parkside Foyer, Level 1			
	Lunch and poster presentations			
Meetings:	Parkside Auditorium	Parkside G04	Parkside 110B	Parkside 110A
	Pharmacogenomics SIG	New Zealand Forum	Toxicology and Drug Discovery SIG	Neuro- behavioural SIG
13:30 – 15:30	Parkside 110B	Parkside Auditorium	Parkside G04	Parkside 110A
	Oral presentations 1	Oral presentations 2	Oral presentations 3: Clinical Trainee	Oral presentations 4
Chairs	Dr Betty Exintaris	A/Prof Lynne Emmerton	Dr Matt Doogue	Dr David Shackelford
13:30 – 13:45	The effect of ageing on paracetamol pharmacokinetics and toxicity in Fischer 344 rats - 120 Mr John Mach, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney Medical School, The University of Sydney	What parents want to know about attention-deficit hyperactivity disorder (ADHD)- A qualitative investigation - 128 Miss Rana Ahmed, The Faculty of Pharmacy, The University of Sydney	Is the process for approval of high cost drugs for off-formulary use leading to clinically appropriate outcomes? - 136 Dr Catherine Lucas, Department of Clinical Pharmacology, Royal Brisbane and Women's Hospital	Differential effects of mango peel sub-fractions on lipid accumulation in 3T3-L1 adipocyte cells - 144 Mr Meng-Wong Taing, School of Pharmacy, The University of Queensland
13:45 – 14:00	NOX2B: A Novel Splice Variant of NOX2 That Promotes Reactive Oxygen Species (ROS) Production in Macrophages - 121 Dr Stavros Selemidis, Department of Pharmacology, Monash University	The influence of disease and other factors on adherence - 129 Miss Piyanan Assawasuwannakit, School of Pharmacy, University of Otago, NZ	The performance of the Cockcroft-Gault, MDRD and CKD-EPI equations in predicting gentamicin clearance - 137 Dr Paul Chin, Department of Clinical Pharmacology, Christchurch Hospital, NZ, Department of Medicine, University of Otago, NZ	The preparation and characterisation of polypyrrole particles for tuneable drug delivery - 145 Mr Zaid Aqrave, The University of Auckland, NZ
14:00 – 14:15	Bitter taste receptor agonists are novel bronchodilators of small airways in mouse lung slices - 122 Dr Jane Bourke, Dept of Pharmacology, University of Melbourne	Strategies used to support patients' adherence to medication: a national survey of community pharmacists - 130 Mrs Sarab Mansoor, Faculty of Pharmacy, The University of Sydney	Describing the use of antibiotics in acute exacerbations of chronic obstructive pulmonary disease - 138 Dr Mitchell McKean, Princess Alexandra Hospital	Characterisation of emulsions as potential saliva substitutes in xerostomia - 146 Miss Sara Hanning, School of Pharmacy, University of Otago, NZ
14:15 – 14:30	Screening potential skin sensitizers using high throughput direct peptide activity assay - 123 Dr Sussan Ghassabian, Centre for Integrated Preclinical Drug Development, University of Queensland	Beyond expectations? Do pharmacists perform clinical interventions when carrying out adherence support medication reviews? - 131 Dr Rhiannon Braund, School of Pharmacy, University of Otago, NZ	Cytochrome P450 2C19 genotyping cost-effective for guiding clopidogrel treatment in Australia - 139 Dr Michael Sorich, Sansom Institute, University of South Australia	Conformational stability of various proteins in solid lipid matrices prepared by melting and cooling - 147 Mr Farrukh Zeeshan, School of Pharmacy, University of Otago, NZ
14:30– 14:45	The antimicrobial peptide LL-37 inhibits migration of the prostate cancer cells - 124 Ms Yan Tu, Department of Pharmacology, University of Melbourne	Asthma management in intellectual disability (ID) - identifying opportunities for the pharmacist - 132 Mrs Sharon Davis, Faculty of Pharmacy, The University of Sydney	Liver Transplant Donor and Recipient CYP3A5 and ABCB1 Genetics and Tacrolimus Pharmacokinetics - 140 Dr Janet Collier, Disc Pharmacology, University of Adelaide	PEGylated surfactants inhibit the digestion of co-formulated triglycerides in a PEG chain length dependent manner - 148 Miss Orlagh Feeney, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
14:45 – 15:00	Expression and localisation of Pannexin-1 Hemichannels in human colon in health and disease - 125 Miss Erica Diezmos, Depts of Pharmacology, School of Medical Sciences, University of New South Wales	Effects of three different forms of inhaler technique education for health care professionals on patient asthma outcomes - 133 Dr Sinthia Bosnic-Anticevich, The University of Sydney	Pro-migratory actions of prostacyclin in breast cancer cells that over-express cyclooxygenase-2 - 141 Dr Sarah Allison, Pharmacogenomics and Drug Development, Faculty of Pharmacy, The University of Sydney	The lymphatic system is critical in maintaining the prolonged circulation of monoclonal antibodies and in promoting absorption from the subcutaneous injection site - 149 Ms Annette Dahlberg, Monash Institute of Pharmaceutical Sciences, Monash University
15:00 – 15:15	Neurokinin A potentiates spontaneous and purinergic evoked smooth muscle contraction and bladder afferent activity responses via activation of mouse bladder urothelial and detrusor NK2 receptors - 126 Mr Luke Grundy, Bond University	Community pharmacy as a health hub: meeting the needs of people with chronic conditions - 134 Ms Sara McMillan, Griffith Health Institute, Griffith University	A new pharmacokinetic abnormality among patients with 5-fluorouracil toxicity - 142 Dr John Duley, School of Pharm, PACE, University of Queensland, Mater Medical Research Institute	Stabilisation of amorphous indomethacin in aqueous suspensions: Effect of polymer addition method - 150 Dr Dorothy Saville, School of Pharmacy, University of Otago, NZ
15:15 – 15:30	Inflammatory biomarkers predict response and toxicity to FOLFOX in colorectal cancer patients - 127 Miss Thien-Phuoc Huynh, Discipline of Pharmacology, The University of Sydney	"Knowing how" is not enough: why people with asthma do not maintain correct inhaler technique over time - 135 Ms Ludmila Ovchinnikova, The Faculty of Pharmacy, The University of Sydney	Anti-proliferative actions of sorafenib and its major metabolites in MDA-MB-231 breast cancer cells - 143 Dr Pei (Sarah) Cui, Faculty of Pharmacy, The University of Sydney	Understanding the role of device design on the aerosolisation of a carrier-based dry powder inhaler - 151 Qi Zhou, Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney

Monday 3 December, 2012 cont.

15:30 – 16:00	Afternoon tea			
16:00 – 18:00	Parkside 110A	Parkside Auditorium	Parkside G04	Parkside 110B
	Oral presentations 5	Oral presentations 6	Oral presentations 7	Oral presentations 8
Chairs	Dr David Foster Dr Andrew Rowland	A/Prof Sarah Hilmer	Dr Mark Hutchinson	Prof Greg Monteith
16:00 – 16:15	Impact of Alzheimer's disease on drug transport across the blood-brain barrier - 152 Ms Dharmini Mehta, Drug Delivery Disposition and Dynamics, Monash University	Renal function estimation in drug development: should East Asian ethnicity be considered? - 160 Mr Daniel Trajkov, Faculty of Pharmacy, The University of Sydney	β-Alanine, A GABA_C partial agonist becomes antagonist when one residue at loop C of binding pocket mutated - 168 Mr Moawiah Naffaa, Faculty of Pharmacy, The University of Sydney	The role of the secretory pathway calcium ATPases (SPCAs) in breast cancer - 176 Mrs Jane Lee, School of Pharmacy, The University of Queensland
16:15 – 16:30	Contribution of rCt1 to the uptake and toxicity of copper and platinum anticancer drugs in sensory neurons - 153 Dr Johnson Liu, School of Pharmacy, Faculty of Health Science, University of Tasmania, Dept of Pharmacol & Clin Pharmacol, FMHS, University of Auckland, NZ	The influence of phenotypic and genotypic patient characteristics on allopurinol and oxypurinol pharmacokinetics in patients with gout - 161 Mr Daniel Wright, School of Pharmacy, University of Otago, NZ	Analgesic efficacy and mode of action of a small molecule angiotensin type 2 receptor antagonist in a rat model of prostate cancer induced bone pain. - 169 Mr Arjun Muralidharan, Centre for Integrated Preclinical Drug Development, School of Pharmacy, The University of Queensland	Structure-function analysis of orthosteric, allosteric and bitopic ligand binding at adenosine A1 receptors - 177 Ms Anh Thi Ngoc Nguyen, Monash Institute of Pharmaceutical Sciences, Monash University
16:30 – 16:45	PEGylation improves the lymphatic disposition of interferon 2α after subcutaneous and intravenous administration in rats and consequently improves the treatment of lymph-metastatic breast cancer - 154 Dr Lisa Kaminskas, Monash Institute of Pharmaceutical Sciences, Monash University	The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin - 162 Dr Sophie Stocker, Dept of Bioengineering and Therapeutic Sciences, University of California San Francisco, USA	Attenuation of Toll-like receptor 4 reduces reward-like behaviours in mice - 170 Mr Jonathan Henry Jacobsen, Physiology, School of Medical Sciences, University of Adelaide	Glucocorticoids inhibit breast tumour cell migration but increase metastasis to the lung in a mouse model of breast cancer - 178 Ms Ebony Fietz, The University of Melbourne
16:45 – 17:00	Association between intra-renal P-gp expression and cyclosporine concentrations in renal transplantation - 155 A/Prof Benedetta Sallustio, The Queen Elizabeth Hospital, The University of Adelaide	Gentamicin directed therapy: Which program to use? - 163 Mr Shaun Kumar, School of Medical Sciences, University of New South Wales, Department of Clinical Pharmacology, St Vincent's Hospital	Potent anti-inflammatory effects of andrographolide and its major metabolite, andrographolide sulfonate - 171 Prof Gerald Muench, University of Western Sydney	Oleoyl-L-glycine and N-arachidonoyl-glycine inhibit the glycine transporter GlyT2 - 179 Prof Robert Vandenberg, Discipline of Pharmacology, Bosch Institute, The University of Sydney
17:00 – 17:15	Population pharmacokinetic modelling of colistin methanesulphonate and formed colistin in patients on continuous ambulatory peritoneal dialysis - 156 Dr Cornelia Landersdorfer, Centre for Medicine Use and Safety, Monash University	Clozapine-induced myocarditis: characterisation using case-control design - 164 Dr Kathlyn Ronaldson, Department of Epidemiology and Preventive Medicine, Monash University	Anaesthesia increases markers of inflammation and pro-inflammatory cytokines in serum and hippocampus: relationship to post-operative cognitive dysfunction - 172 Dr Jennifer Callaway, Pharmacology Department, University of Melbourne	A bitopic (orthosteric/allosteric) ligand can differentiate monomeric from dimeric forms of a Family A G protein-coupled receptor - 180 Dr Jonathan Lane, Monash Institute of Pharmaceutical Sciences
17:15 – 17:30	Development of a population model of early rheumatoid arthritis disease progression treated with methotrexate, sulfasalazine and hydroxychloroquine - 157 Ms Jessica Wojciechowski, Australian Centre for Pharmacometrics, University of South Australia	Relationship between high risk prescribing and adverse outcomes in people with and without Alzheimer's disease - 165 Dr Danijela Gnjidic, Faculty of Pharmacy, The University of Sydney, Clinical Pharmacology Department, Royal North Shore Hospital, Sydney Medical School, The University of Sydney	Hypoxia-inducible factor - 1 (HIF-1) prolyl hydroxylase inhibitors have neuroprotective actions in a neonatal rat model of hypoxic-ischemic brain injury - 173 Dr Nicole Jones, Department of Pharmacology, University of New South Wales	Delineating determinants of cooperativity, affinity and bias for mGlu5 allosteric modulators - 181 Dr Karen Gregory, Drug Discov Biol, MIPS, Monash Univ, Dept of Pharmacol & Ctr for Neurosci Drug Discov, Vanderbilt University Medical Centre, USA
17:30 – 17:45	Evaluation of current warfarin pharmacokinetic-pharmacodynamic models and dosing algorithms - 158 Miss Verity Pearson-Dennett, Australian Centre for Pharmacometrics, University of South Australia	A Collaboration to Measure ADEs in three District Health Boards - 166 Dr Chris Cameron, Department of Clinical Pharmacology, Capital & Coast DHB, NZ	Oxycodone-induced activation of Toll-Like Receptor 4 contributes to drug reward - 174 Dr Mark Hutchinson, Discipline of Physiology, University of Adelaide	Nordihydroguaiaretic acid activates human TRPA1 - 182 Prof Mark Connor, Australian School of Advanced Medicine, Macquarie University
17:45 – 18:00	Development and application of a mechanism-based model for the multistage life-cycle of murine malaria - the effect of single and multiple dose dihydroartemisinin - 159 Dr Kashyap Patel, Centre for Medicine Use and Safety, Monash University	Risk management plans in the Australian regulatory environment - 167 Miss Natalie Raffoul, Faculty of Pharmacy, The University of Sydney	Exploring cannabinoid receptor activity of synthetic compounds identified in "Spice" -related products using novel assays for CB1 and CB2 receptor activation - 175 Ms Jordyn Stuart, Australian School of Advanced Medicine, Macquarie University	Pharmacoregulation of distinct molecular phenotypes of the human CaSR caused by naturally occurring mutations - 183 Dr Katie Leach, Monash Institute of Pharmaceutical Sciences, Monash University
18:00	ASCEPT & APSA Presidents' Function (by invitation only)			
18:30 – 22:00	AAPS Student Dinner Bungalow 8, 3 Lime Street, Sydney			

Tuesday 4 December, 2012

08:00 – 09:00	Parkside Foyer, Level 1			
	Poster presentations			
	 SPONSORED BY			
	Parkside 110A			
Meeting:	Clinical Pharmacology SIG			
09:00 – 10:00	Parkside Auditorium			
	Plenary 3: APSA Lecture			
	Newer drugs in older people: better the devil you know when it comes to medication safety? - 200			
	Prof Gregory Peterson, Professor of Pharmacy and Head of School, University of Tasmania			
	 SPONSORED BY			
10:00 – 10:30	Morning tea			
10:30 – 12:30	Parkside Auditorium	Parkside 110A	Parkside 110B	Parkside G04
Chairs	Symposium 5: Metabolites and medication safety	Symposium 6: Ion channels in drug discovery: developing safer medications	Symposium 7: Drug safety-clinical pharmacology at the epicentre	Symposium 8: Novel drug delivery strategies with clinical applications
	Dr David Foster Dr Andrew Rowland	Prof Greg Monteith	Dr Janet Coller	Dr Des Williams
	Complex patients, complex models - PBPK made easy? - 201 Emeritus Prof Geoff Tucker, SimCYP, UK SPONSORED BY   Pharmacokinetic and pharmacodynamic modelling of PR-104: dissecting the "bystander effect" of hypoxia-activated metabolites - 202 Dr Kashyap Patel, Monash University Metabolic drug activation in rheumatoid arthritis and drug toxicity - 203 Dr Michael Weise, University of South Australia	Structure activity studies and therapeutic potential of venom peptides that target acid-sensing ion channels - 204 Dr Lachlan Rash, The University of Queensland Consequences of human TRPV4 mutations: implications for drug targeting and disease - 205 Prof Peter McIntyre, RMIT University GABA_A receptors and flavonoids: Achieving subtype selectivity anxiolytics devoid of sedative effects - 206 Prof Mary Chebib, The University of Sydney TRPM7 in cardiac hypertrophy: more than just a cation channel - 207 Dr Tamara Paravicini, The University of Queensland	Systematic Reviews of Adverse Effects – Why Bother? - 208 Dr Yoon Loke, University of East Anglia, UK Public health: drug safety epidemiology - 209 Dr Kathlyn Ronaldson, Monash University Pharmacogenomics of drug safety - 210 Prof Elizabeth Phillips, Murdoch University The safety of medicines in older people - 211 Prof David Le Couteur, The University of Sydney	Drug delivery to the eye: barriers and delivery system prospects - 212 Prof Arto Urtti, University of Helsinki, Finland Translational pulmonary drug delivery - 213 Prof Kim Chan, The University of Sydney Utilizing oligoarginine to enhance cellular uptake of PECA nanoparticles - 214 Mr Jasper Chiu, School of Pharmacy, University of Otago, NZ Bio-mimetic prodrugs to promote lymphatic transport of immunomodulators: A balance between digestive stability and ease of re-esterification - 215 Mr Sifei Han, Monash Institute of Pharmaceutical Sciences, Monash University Enhanced exposure of a chemotherapeutic agent to the lymphatic system with the use of nano-sized and PEG-capped drug vectors - 216 Ms Gemma Ryan, Monash Institute of Pharmaceutical Sciences, Monash University
12:30 – 13:30	Parkside Foyer, Level 1			
	Lunch and poster presentations			
	Parkside G04	Parkside 110A	Parkside 110B	Parkside Auditorium
Meetings:	Urogenital and Gastrointestinal SIG	Drug Disposition and Response SIG	Education Forum	Cardiovascular SIG

Tuesday 4 December, 2012 cont.

13:30 – 15:30	Parkside Auditorium Oral presentations 9: ASCEPT Oral Prize	Parkside G04 Oral presentations 10	Parkside 110A Oral presentations 11	Parkside 110B Oral presentations 12
Chairs	Dr Barbara Kemp-Harper	Prof Greg Peterson	Dr Sophie Stocker	Dr Karen Andrews Prof Rob Widdop
13:30 – 13:45	Expression, regulation, deorphanisation and putative nutrient-sensing function of taste GPCRs in the heart - 217 Mr Simon Foster, School of Biomedical Sciences, University of Queensland	Safe to crush? Pilot study into solid dosage form modification in aged care - 225 Dr Greg Kyle, University of Canberra	High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS - 233 Dr Sussan Ghassabian, Centre for Integrated Preclinical Drug Development, University of Queensland	Heterogeneous Vasoconstrictor Responses Amongst Men And Women - 241 Miss Ameha Jaghoori, School of Medicine, University of Adelaide
13:45 – 14:00	A reduction in random between subject variability is not mandatory when adding a new covariate - 218 Mr Chakradhar Lagshetty, School of Pharmacy, University of Otago, NZ	Can software assist the home medicines review process by identifying clinically relevant drug-related problems? - 226 Mr Colin Curtain, School of Pharmacy, University of Tasmania	Prescribing in the elderly - cytochrome P450 (CYP) enzyme inhibitors and substrates - 234 Dr Karen Kerr, School of Biomedical Sciences & Pharmacy, University of Newcastle	The role of NOX2 NADPH oxidase in macrophage polarisation - 242 Ms Caitlin Lewis, Department of Pharmacology, Monash University
14:00 – 14:15	Ghrelin gene-derived peptides have protective roles in the cerebral circulation and brain - 219 Miss Jacqueline Ku, Department of Pharmacology, Monash University	An observational study of pharmacists' interventions to minimise medication misadventures in paediatric inpatients - 227 Ms Hesty Ramadaniati, School of Pharmacy, Curtin University	Fruit juices as perpetrators of drug interactions: The role of intestinal transporters - 235 Mr Michael Dolton, Faculty of Pharmacy, The University of Sydney	An investigation of the anti-inflammatory role of nitroxyl (HNO) on the endothelium - 243 Dr Karen Andrews, Vascular Pharmacology, Baker IDI Heart and Diabetes Institute
14:15 – 14:30	Calcium dependent regulation of multidrug resistance-associated protein 3 (MRP3/ABCC3) gene expression in a model of epithelial-mesenchymal transition (EMT) - 220 Ms Teneale Stewart, School of Pharmacy, The University of Queensland	Prevalence and factors associated with antidepressant use in Tasmanian nursing homes - 228 Ms Laura Trillini, Unit for Medication Outcomes, Research and Education (UMORE) University of Tasmania	Ion chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties - 236 Mr Madhur Shastri, School of Pharmacy, University of Tasmania	Differential roles of KCNQ4 and KCNQ5 potassium channels in cerebral artery reactivity - 244 Dr Preet Chadha, Division of Biomedical Sciences, St George's, University of London
14:30 – 14:45	Small airway reactivity to constrictors is differentially altered by chronic and acute inflammatory stimuli - 221 Ms Chantal Donovan, Department of Pharmacology, University of Melbourne	Prevalence of frailty and number of medicines use in elderly Australian: A comparison of four frailty measures - 229 Miss Imaina Widagdo, School of Pharmacy and Medical Sciences, University of South Australia	The physicochemical stability of diluted iron polymaltose in polyvinyl chloride infusion bags - 237 Dr Rahul Patel, School of Pharmacy, University of Tasmania	Hydrogen sulfide protects endothelial function under conditions of oxidative stress - 245 Dr Joanne Hart, School of Medical Sciences, RMIT University
14:45 – 15:00	Characterisation of the hybrid orthosteric/allosteric bitopic nature of TBPB at the M1 muscarinic ACh receptor - 222 Mr Peter Keov, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University	Pharmacy staff perspectives on patient safety issues involved in the supply of dose administration aids - 230 Mr Ramesh Walpola, Faculty of Pharmacy, The University of Sydney	The physicochemical stability of Ceftazidime or Cephazolin in peritoneal dialysis fresenius infusion bag - 238 Miss Siti Farahwahida Shikh Mohd Fadzilah, School of Pharmacy, University of Tasmania	Carvedilol induces greater control by PDE3 of β_2- than β_1-adrenoceptor-mediated inotropic effects in human failing myocardium while PDE4 has no effect - 246 A/Prof Peter Molenaar, School Biomed Sci, QUT and School of Medicine, The University of Queensland
15:00 – 15:15	CYP2B6*6 mutation significantly reduces in vitro N-demethylation of ketamine enantiomers - 223 Mr Yibai Li, Discipline of Pharmacology, University of Adelaide	Key health professionals' views of prescribing resources for older patients - 231 Ms Paulina Stehlik, Centre for Medication Use and Safety, Monash University	A practical synthesis of D-rhamnose building blocks for synthetic bacterial O-polysaccharide conjugate vaccines - 239 Mr Matthew Zunk, School of Pharmacy, Griffith University, Institute for Glycomics, Griffith University	Impact of the putative nitroxyl (HNO) donor 1-nitrosocyclohexyl acetate (1-NCA) on the intact rodent heart - 247 A/Prof Rebecca Ritchie, Heart Failure Pharmacology, Baker IDI Heart & Diabetes Institute
15:15 – 15:30	Simultaneous deletion of the α_{1A}-adrenoceptor and P2X₁ purinoceptor generates male mice which are infertile - 224 Mr Carl White, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University	Major medication discrepancies in patients with type 2 diabetes mellitus (T2DM), referred from primary care, to a tertiary ambulatory diabetes centre - 232 Miss Madonna Fiona Azzi, Faculty of Pharmacy - The University of Sydney	Glutamate efflux from brain to blood - transport and uptake studies in a bovine in vitro blood-brain barrier model - 240 Dr Birger Brodin, Department of Pharmacy, University of Copenhagen, Denmark	Compound 21, a synthetic AT2 receptor agonist, evokes neuroprotection in a conscious rat model of ischaemic stroke - 248 Mr Lachlan Facey, Monash University
15:30 – 16:00	Afternoon tea			
16:00 – 17:00	Parkside Auditorium Plenary 4: ASCEPT Lecture Much ado about NSAIDs - 249 Prof Kathie Knights, Department of Clinical Pharmacology, Flinders University			
17:00 – 18:00	Parkside 110A APSA AGM		Parkside Auditorium ASCEPT AGM	
19:00 – 22:30	Conference Dinner Dockside, The Balcony Level, Cockle Bay Wharf, Darling Harbour			

Wednesday 5 December, 2012

09:00 – 10:00	Parkside Auditorium		
	APSA Medal Oration 2012 Emeritus Prof Andrew Gilbert, University of South Australia		
10:00 – 10:30	Morning tea		
Chairs	Parkside 110A	Parkside 110B	Parkside Auditorium
	Symposium 9: Joint ASCEPT-APSA education symposium	Symposium 10: Sex differences in chronic diseases: implications for future therapies	Symposium 11: Medication safety – systems and practice
	Dr Liz Davis Prof Ieva Stupans	Dr Tamara Paravicini	Prof Andrew McLachlan
	The best of both worlds: creating an inclusive learning environment for experimental and clinical pharmacology - 301 Dr Hilary Lloyd, The University of Sydney The devil is in the detail - 302 Dr Richard Loiacono, Monash University Teaching the 'new' prescribers: the challenges of knowledge, attitudes and skills - 303 Prof Kathie Knights, Flinders University	Myocardial stress and ischemic injury - sex and sex steroid influences - 304 Prof Lea Delbridge, The University of Melbourne Y chromosome dependent blood pressure regulation in the SHRSP is mediated, in part, by the renal renin angiotensin system - 305 Dr Amanda Sampson, Baker IDI Heart and Diabetes Institute Sex differences in the role of the renin-angiotensin system in the regulation of arterial pressure and renal function - 306 A/Prof Kate Denton, Monash University Gene-environment interactions and sexual dimorphism in mouse models of brain disorders - 307 A/Prof Anthony Hannan, University of Melbourne Association of the human Y chromosome and cardiovascular disease risk - 308 Prof Fadi Charchar, University of Ballarat	Systems based approach to drug safety - 309 Dr Romano Fois, The University of Sydney CareTrack as a methodology and relevance for med safety - 310 Prof Ric Day, St Vincent's Hospital Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case-Control Study - 311 Prof Emily Banks, Australian National University
12:30 – 13:30	Parkside Foyer, Level 1 Lunch and poster presentations		
Chairs	Parkside Auditorium	Parkside 110B	Parkside 110A
	Denis Wade Johnson & Johnson New Investigators Prof David Le Couteur	Oral presentations 13 Dr Liz Davis	Oral presentations 14 A/Prof Simon Bell
13:30 – 13:45	Pharmacometrics methods to individualise dose - 312 Dr Stephanie Hennig, The University of Queensland	Does evidence-based education on complementary medicines change students' attitudes and likelihood of recommending them in a pharmacy setting? - 322 Mrs Liesl Blott, Curtin University	Safety before efficacy? Australian pharmacists' attitude to homeopathic products in pharmacy - 324 Ms Suzanne Schultz, School of Pharmacy and Medical Sciences, University of South Australia
13:45 – 14:00		Online support for pharmacology practical teaching - 317 Prof David Dewhurst, University of Edinburgh and British Pharmacological Society, University of Edinburgh, UK	Exploring community pharmacists' views on medication-safety management - 325 Ms Rachel George, The University of Sydney
14:00 – 14:15	Preventing resistance of bacterial "superbugs" by synergistic combinations of available antibiotics - 313 Dr Jurgen Bullitta, Monash University	The development of an experiential and learning programme for undergraduate pharmacy students at Alcohol and Drug Services - 318 Dr Juanita Westbury, Unit for Medication Outcomes, Research and Education (UMORE), University of Tasmania	Improving consumer access to medicines: innovative medicines reclassification in New Zealand (NZ) - 326 Ms Natalie Gauld, University of Auckland, NZ
14:15 – 14:30		An international survey of health literacy education within schools of pharmacy - 319 Mr Glen Swinburne, Monash University	Community-acquired pneumonia: why aren't national antibiotic guidelines followed? - 327 Mr Maher Almatar, University of Tasmania
14:30– 14:45	Positive and negative outcomes from medicines in older adults - 314 Dr Danijela Gnjidic, The University of Sydney	Development of a national medication safety online training course: because safety is no accident - 320 Dr Alexandra Bennett, NSW Therapeutic Advisory Group	Implications of the Personally-Controlled Electronic Health Record for community pharmacy - 328 A/Prof Lynne Emmerton, School of Pharmacy, CHIRI, Curtin University
14:45 – 15:00		Experimental design and statistical analysis in intermediate medical sciences curricula - a pilot study - 321 Dr Tina Hinton, School of Medical Sciences (Pharmacology), The University of Sydney	Challenges and safety concerns for community pharmacy personnel in the provision of services to young people - 329 Ms Emma Horsfield, School of Pharmacy, The University of Auckland, NZ
15:00 – 15:15	Allosteric modulation of G protein-coupled receptors - 315 Dr Celine Valant, Drug Discovery Biology	Effect of an educational workshop on pharmacists' knowledge, attitudes and beliefs towards low back pain (LBP) - 316 Miss Christina Abdel Shaheed, Faculty of Pharmacy, The University of Sydney	End-users' perceptions of the electronic medication repository, MedView - 330 Dr Safeera Hussainy, Centre for Medicine Use and Safety, Monash University
15:15 – 15:30		Use of an audience response system and collaborative learning increases engagement in post graduate pharmacy - 323 Dr Slade Matthews, Pharmacology, Sydney Medical School, The University of Sydney	Management of high blood pressure in pregnant women attending an Australian maternity hospital - 331 Mrs Amyna Helou, Centre for Medicine Use and Safety, Monash University
15:30 – 16:00	Parkside Auditorium Awards and close		

ASCEPT - APSA poster presentations

Monday 3 December, 8.00am – 9.00am and 12.30pm – 1.30pm

PARKSIDE FOYER, LEVEL 1

Board number	Abstract title	Presenter	Paper reference	Session theme
400	Pharmacovigilance and computational chemistry approaches to predicting torsades de pointes	Christabel Abalo	400	Cardiovascular
401	Tocomin restores endothelium-dependent relaxation in diabetic rat aorta	Saher Ali	401	Cardiovascular
402	Resistin, a novel adipokine, increases renal SNA and reduces BAT SNA using PI3-kinase or ERK 1/2 mediated mechanisms	Emilio Badoer	402	Cardiovascular
403	Head-to-head comparison of the relative anti-fibrotic efficacy of H2 relaxin to clinically used ACE inhibitor (enalapril)	Hasangika Bodaragama	403	Cardiovascular
404	Comparing the anti-fibrotic actions of relaxin vs an angiotensin AT1 receptor blocker and AT2 receptor agonist	Jacqueline Chew	404	Cardiovascular
405	Is insulin-mediated sensitization of platelets to NO in diabetics TxNIP-dependent?	Cher-Rin Chong	405	Cardiovascular
406	Utilisation of antithrombotics for secondary stroke prevention at hospital discharge	Ashraf Eissa	406	Cardiovascular
407	Blood pressure lowering therapy for stroke patients at hospital discharge	Ashraf Eissa	407	Cardiovascular
408	AT2 and Mas receptor agonists as neuroprotective drugs for stroke	Megan Evans	408	Cardiovascular
409	Compound 21, a synthetic AT2 receptor agonist, evokes neuroprotection in a conscious rat model of ischaemic stroke	Lachlan Facey	248	Cardiovascular
410	Expression, regulation, deorphanisation and putative nutrient-sensing function of taste GPCRs in the heart	Simon Foster	217	Cardiovascular
411	Capsaicin relaxes arteries via NO-dependent and independent mechanisms	Kirsty Fuller	411	Cardiovascular
412	Vanilloid-like agents inhibit platelet aggregation in vitro	Dom Geraghty	412	Cardiovascular
413	Psychotropic drugs inhibit the acetylcholine receptor-operated potassium current (IK.ACh) by different mechanisms in guinea-pig atrial myocytes	Yukio Hara	413	Cardiovascular
414	Effect of diabetes on the production and vasoactivity of hydrogen sulfide in rat middle cerebral arteries	Joanne Hart	414	Cardiovascular
415	Contractile recovery induced by pharmacological conditioning with GTN & cariporide at cardioplegia is associated with mitochondrial protective signaling in a model of donor heart preservation	Mark Hicks	415	Cardiovascular
416	Relaxation of rat isolated pulmonary arteries by a novel vasodilator, BAY41-8543	Richard Hughes	416	Cardiovascular
417	Heterogeneous vasoconstrictor responses amongst men and women	Amenah Jaghoori	241	Cardiovascular
418	Pharmacological profiling of angiotensin II and bradykinin receptor heteromers	Elizabeth Johnstone	418	Cardiovascular
419	Region-dependent contribution of the T-type voltage-operated calcium channel to rat renal vascular contraction	Makhala M Khammy	419	Cardiovascular
420	Brain infarct volume after permanent focal ischemia is not dependent on Nox2 expression	Hyun Ah Kim	420	Cardiovascular
421	Ghrelin gene-derived peptides have protective roles in the cerebral circulation and brain	Jacqueline Ku	219	Cardiovascular
422	Neuroprotective Effect of an Angiotensin Receptor-2 Agonist Following Cerebrals ischemia In Vitro and In Vivo	Seyoung Lee	422	Cardiovascular
423	The role of NOX2 NADPH oxidase in macrophage polarisation	Caitlin Lewis	242	Cardiovascular
424	Endothelin and endothelin receptor antagonism in rat isolated cerebral arteries: relevance for subarachnoid haemorrhage	Yohannes Mamo	424	Cardiovascular
425	Chronic NaHS treatment protects vascular function by reducing oxidative stress in streptozotocin-induced diabetes in mice	Hooi Hooi Ng	425	Cardiovascular
426	Review of epidemiology and management of atrial fibrillation in developing countries	Tu Nguyen	426	Cardiovascular
427	An allosteric enhancer of the adenosine A1 receptor improves cardiac function following ischaemia in isolated murine hearts	Roselyn Rose Meyer	427	Cardiovascular
428	The DPP-4 inhibitor linagliptin improves endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose	Salheen Salheen	428	Cardiovascular
429	Direct stimulation of AT2R and the MasR prevents TNF α -induced endothelial inflammation	Amanda Sampson	429	Cardiovascular
430	Review of antithrombotic risk assessment tools for stroke prevention in atrial fibrillation patients	Yishen Wang	430	Cardiovascular
465	Medication safety issues in older Australians: results from a national medicines census	Jo Barnes	465	Clinical Pharmacology
466	Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription medicine use in community pharmacies	Jo Barnes	466	Clinical Pharmacology
467	The impact of medications on robust and frail older people with falls	Sarah Hilmer	467	Clinical Pharmacology
468	An essential medicines list for children: Are they still therapeutic orphans?	Noel Cranswick	468	Clinical Pharmacology
469	The ABCD of Clinical Pharmacokinetics	Matthew Doogue	469	Clinical Pharmacology
470	A population pharmacokinetic (popPK) model to describe the renal clearance and the effect of transporter genetic variants on the pharmacokinetics of metformin in patients with type 2 diabetes mellitus (T2DM)	Janna Duong	470	Clinical Pharmacology
471	Population pharmacokinetics of factor VIII in paediatric patients	Kirsten Jensen	471	Clinical Pharmacology
472	The pharmacokinetics of paracetamol and its metabolites: A population approach to investigating hepatic intrinsic clearance in old age	Claire Johnston	472	Clinical Pharmacology
473	Baseline plasma urate: the only determinant for dosage selection of allopurinol	Diluk Kannangara	473	Clinical Pharmacology
474	Optimising ribavirin therapy for hepatitis C patients	Ashmit Kaur	474	Clinical Pharmacology
475	High dose intravenous paracetamol in major surgical patients	Julia Kennedy	475	Clinical Pharmacology
476	Dosage adjustment of medications in patients with renal impairment: how consistent are drug information sources?	Aarati Khanal	476	Clinical Pharmacology
477	Development and validation of software to calculate the drug burden index: a pilot study	Lisa Kouladjian	477	Clinical Pharmacology
478	Gentamicin directed therapy: Which program to use?	Shaun Kumar	163	Clinical Pharmacology
479	Identifying effective strategies to prevent drug-drug interactions in hospital: a user-centered approach	Olivia Missiakos	479	Clinical Pharmacology
480	Ropivacaine concentrations (total and unbound) following transverse abdominis plane (TAP) block for analgesia following abdominal surgery - A pilot study	Raymond G Morris	480	Clinical Pharmacology

Board number	Abstract title	Presenter	Paper reference	Session theme
481	Impact of pharmacist-led dosing of vancomycin and aminoglycosides in hospitalised patients	Daniel O'Brien	481	Clinical Pharmacology
482	Development of a population PKPD model to describe the effect of paracetamol on the International Normalised Ratio (INR)	Katie H Owens	482	Clinical Pharmacology
483	Assessment of frailty and prescribing criteria in older people: A systematic review	Arjun Poudel	483	Clinical Pharmacology
484	Risk management plans in the Australian regulatory environment	Natalie Raffoul	167	Clinical Pharmacology
485	Allopurinol Hypersensitivity (AH): An examination of all published cases, 1950-2011	Sheena Ramasamy	485	Clinical Pharmacology
486	Association between age, lean body weight, frailty and inducible SIRT1 expression response to sera: the CHAMP study	Shajjia Razi	486	Clinical Pharmacology
487	An evaluation of switches in therapeutic equivalents as triggers for adverse event monitoring	David Reith	487	Clinical Pharmacology
488	Measuring drug concentrations, analytical methods and issues	Andrew Rowland	488	Clinical Pharmacology
489	New Zealand Formulary - a case study of national formulary development	Bryan Simpson	489	Clinical Pharmacology
490	Evaluation of formulary applications in Australian paediatric hospitals	Yashwant Sinha	490	Clinical Pharmacology
491	Diagnostic errors in older patients: A systematic review of the incidence and causes in thirteen prevalent conditions	Jennifer Martin	491	Clinical Pharmacology
492	An evaluation of a change in dosing regimen of gentamicin in neonates	Louise Thomas	492	Clinical Pharmacology
493	Anti-arthritis and anti-proteus activities of colloidal metallic silver (CMS)	Michael Whitehouse	493	Clinical Pharmacology
494	Monitoring the anti-proteus activity of colloidal metallic silver (CMS) in vivousing the Metatron/Hunter	Michael Whitehouse	494	Clinical Pharmacology
495	Posterior, subcapsular cataract in association with fludrocortisone acetatetherapy: a case report	Ian Whyte	495	Clinical Pharmacology
496	Evaluating posaconazole use in a patient population	William Wu	496	Clinical Pharmacology
501	Electronic prescribing in St Vincent's hospital and the National Inpatient Medication Chart (NIMC) audit	Brian Egan	501	Clinical Pharmacology Trainee
517	A rapid and sensitive LC-MS method for the quantification of nilotinib in human plasma	Daniel Barratt	517	Drug Disposition and Response
518	Transplacental disposition of rosiglitazone in the maternal fetal unit	Maryam Bazargan	518	Drug Disposition and Response
519	Glucosidation and glucuronidation of mycophenolic acid (MPA) by UDP-glucuronosyltransferase (UGT) 1A and 2B sub-family enzymes	Nuy Chau	519	Drug Disposition and Response
520	Mega-model of voriconazole population pharmacokinetics	Michael Dolton	520	Drug Disposition and Response
521	Cediranib and erlotinib are potent inhibitors of human solute carrier transporters	Rosie Johnston	521	Drug Disposition and Response
522	Liver fibrosis as the major determinant of the altered hepatic uptake of taurocholate in rat model of liver diseases	Peng Li	522	Drug Disposition and Response
523	In vivo bio-distribution of water-dispersible CdTe/CdS quantum dots following intravenous injection	Xiaowen Liang	523	Drug Disposition and Response
524	Intravital imaging of fluorescein transport in the rat liver after intravenous injection	Xin Liu	524	Drug Disposition and Response
525	Effect of liver endothelial cell defenestration on hepatic insulin and glucose uptake	Victoria Cogger	525	Drug Disposition and Response
526	Diurnal variation of CYP1A2 Activity in individuals of South Asian and European Ancestry	Vidya Perera	526	Drug Disposition and Response
527	Inhibition of human UDP-Glucuronosyltransferase 1A (UGT1A) enzymes by three different Tyrosine Kinase Inhibitors (Lapatinib, Pazopanib and Sorafenib): implications for drug interactions and jaundice	Andrew Rowland	527	Drug Disposition and Response
528	In vitro characterisation of the 'albumin effect' on human liver microsomalolanzapine oxidative metabolism	Porn-tipa Korprasertthaworn	528	Drug Disposition and Response
529	Allometric scaling of antimalarial drugs	Ganga Senarathna	529	Drug Disposition and Response
537	Effectiveness of a blended learning approach in delivering advanced drug delivery systems to third year pharmacy students at Curtin University	Yan Chen	537	Education
538	Evaluation as best practice: a case study on interdisciplinary learning and teaching of a Remote Health Experience program at Flinders NT	Pascale Dettwiller	538	Education
539	The eBook 'Pharmacology in One Semester': uses and student evaluation	Sheila Doggrell	539	Education
540	Quality assurance exercise for assessing basic compounding skills of pharmacy students	Jennifer Dolzadelli	540	Education
541	What really makes students 'work ready' - what are Pharmacy students' and their preceptors' considerations?	Jasmina Fejzic	541	Education
542	Bringing competency standards to life for UTAS Bachelor of Pharmacy Undergraduate students	Rose Nash	542	Education
543	The UTAS Pharmacy Students' Road Map	Rose Nash	543	Education
544	Competency of Pharmacy graduates-tool validation and investigation	Joy Spark	544	Education
545	Jack and the beanstalk, climbing the vine of skills - preceptor training for pharmacists	Catherine Spiller	545	Education
546	Supporting Tasmanian hospital pharmacists to mentor pharmacy students	Catherine Spiller	546	Education
547	Fostering deep learning through collaborative learning and peer assessment: A case study in Pharmacology Teaching and Learning	Lisa Tee	547	Education
548	Adding creativity to pharmacy practice: Using Bloom's Taxonomy to develop learning skills in fourth year pharmacy students	Hung Tran	548	Education
593	Computational Modeling of Powder Dispersions in Turbuhaler®	Qi (Tony) Zhou	593	Pharmaceutical Science
594	Elucidating drug release mechanisms of biomacromolecule-containing lipid particles during lipolysis	Philip Christophersen	594	Pharmaceutical Science
595	A comparison study on the effect of dry and moist heat sterilisation on lecithin microemulsions	Khubaib Azahari	595	Pharmaceutical Science
596	UV imaging and flow through Raman spectroscopy: information-rich tools for characterising the dissolution behaviour of furosemide	Sarah Gordon	596	Pharmaceutical Science
597	Higher apparent solubility and faster dissolution rate of amorphous furosemide salt leads to faster Tmax after oral dosing in rats compared to amorphous and crystalline furosemide acid	Line Hagner Nielsen	597	Pharmaceutical Science
598	Addition of hydroxypropyl methylcellulose to furosemide increases physical stability of the amorphous form of furosemide	Line Hagner Nielsen	598	Pharmaceutical Science

Board number	Abstract title	Presenter	Paper reference	Session theme
599	Comparison of two extraction methods prior to chromatographic determination of metabolic fragments of beta-endorphin within inflamed rat tissue	Naghme Asvadi	599	Pharmaceutical Science
600	Polarized light microscopy as a method for analyzing API precipitation in simulated gastric media	Linda Jensen	600	Pharmaceutical Science
601	Stability of risperidone in a novel polyol-based low-aqueous in situ gelling emulsion	Ross Norris	601	Pharmaceutical Science
602	Nicotine retention as the major determinant of percutaneous absorption of nicotine	Rina Kuswahyuning	602	Pharmaceutical Science
603	Oral delivery of nanoparticles to the colon for tumour targeting	Yiming Ma	603	Pharmaceutical Science
604	Implications of the use of thickening agents to aid swallowing of altered medicines: in vitro study	Yady Juliana Manrique-Torres	604	Pharmaceutical Science
605	A mechanistic based approach for enhancing buccal mucoadhesion of chitosan	Emil Meng-Lund	605	Pharmaceutical Science
606	Validation of Microtitre plate assay for <i>Haemophilus influenzae</i> spp. Biofilm	Najla Obaid	606	Pharmaceutical Science
607	Stability of key antioxidant compounds in pūhā (<i>Sonchus oleraceus</i> L.) leaf extracts under different post-harvest processes and storage conditions	Zong-Quan Ou	607	Pharmaceutical Science
608	Optimization of simulated gastric media (FaSSGF) based on rheological characterization of human gastric fluid	Pernille Barbre Pedersen	608	Pharmaceutical Science
609	The effect of haematocrit on insulin levels from dried blood spots for use in clinical studies	Emma Salis	609	Pharmaceutical Science
610	The effect of formulation on the penetration of coated and uncoated zinc oxide nanoparticles into the viable epidermis of human skin in vivo	Washington Sanchez	610	Pharmaceutical Science
611	Allosteric modulation of regulatory protein recruitment to the glucagon-like peptide-1 receptor	Emilia Savage	611	Pharmaceutical Science
612	Targeting -alanyl aminopeptidase in <i>Pseudomonas aeruginosa</i>	Mohamed Sharkasi	612	Pharmaceutical Science
613	Variability of anti-inflammatory diterpenoids from the Northern Kaanju medicinal plant, <i>Dodonaea polyandra</i>	Bradley Simpson	613	Pharmaceutical Science
620	Characterisation of spontaneous activity in the human prostate gland	Basu Chakrabarty	620	Urogenital and Gastrointestinal
621	Effects of stinging nettle leaf extract on smooth muscle contractility in the isolated rat prostate gland	Nicole Eise	621	Urogenital and Gastrointestinal
622	Depressed contractile responses of the bladder detrusor and urothelium/laminapropria following luminal administration of the cytotoxic agent gemcitabine	Stefanie Farr	622	Urogenital and Gastrointestinal
623	Distribution of 5-HT receptors and interacting proteins in human colonic tissue layers	Helen Irving	623	Urogenital and Gastrointestinal
624	Mitomycin C alters urothelial ATP, acetylcholine and PGE2 release in vitro	Sung-Hyun Kang	624	Urogenital and Gastrointestinal
625	Effects of acrolein, a metabolite of Cyclophosphamide and Ifosfamide, on cultured human urothelial cells	Kylie Mills	625	Urogenital and Gastrointestinal
626	P-glycoprotein expression level in treatment - resistant <i>Helicobacter pylori</i> patients	Marhanis Saliyah Omar	626	Urogenital and Gastrointestinal
627	Nerve-evoked and phasic contractions of the rat bladder: effects of low testosterone and treatment with the selective androgen receptor modulator trenbolone	Donna Sellers	627	Urogenital and Gastrointestinal
628	Low prevalence of <i>Helicobacter pylori</i> infection among patients with Ulcerative colitis in Ukraine	Tetyana Ternushchak	628	Urogenital and Gastrointestinal
629	Simultaneous deletion of the α 1A-adrenoceptor and P2X1 purinoceptor generates male mice which are infertile	Carl White	224	Urogenital and Gastrointestinal
630	Complexity in 5-HT3 receptors: An optimized expression system for electrophysiology studies	Nor Syafinaz Yaakob	630	Urogenital and Gastrointestinal

Tuesday 4 December, 8.00am – 9.00am and 12.30pm – 1.30pm

PARKSIDE FOYER, LEVEL 1

Board number	Abstract title	Presenter	Paper reference	Session theme
432	Allosteric modulation of a chemogenetically modified G protein-coupled receptor	Alaa Abdul-Ridha	432	Drug Discovery
433	The effect of morphine on the growth and dissemination of breast tumor in mice	Marie-Odile Parat	433	Drug Discovery
434	Altered purinergic receptor calcium signalling associated with hypoxia in MDA-MB-468 breast cancer cells	Iman Azimi	434	Drug Discovery
435	Functional selectivity at the Adenosine A1 receptor: Implications for cytoprotection	Jo-Anne Baltos	435	Drug Discovery
436	Can interference of GIP activity modulate GPCRs for therapeutic gains?	Kenneth Chinkwo	436	Drug Discovery
437	Activation and acute desensitization of μ -opioid receptor wild-type and mutants with deleted phosphorylation sites	Marina Santiago	437	Drug Discovery
438	Selective GPCR signalling opens TRPV4 expressed in HEK293 cells	William Darby	438	Drug Discovery
439	The binding mode of SB269652: a novel bitopic ligand at the dopamine D2 receptor	Christopher Draper-Joyce	439	Drug Discovery
440	Antitumour actions of the synthetic Omega-3 17,18-epoxyeicosanoic acid in breast cancer cells	Herryawan Ryadi Eziwar Dyari	440	Drug Discovery
441	Glucocorticoids inhibit breast tumour cell migration but increase metastasis to the lung in a mouse model of breast cancer	Ebony Fietz	178	Drug Discovery
442	Identification of novel allosteric modulators of the α 1A and β 2 adrenoceptors	Angela Finch	442	Drug Discovery
443	Inhibition of human haematological malignant cell line growth by capsaicin is not TRPV1-mediated	Dom Geraghty	443	Drug Discovery
444	Investigation of activation mechanism of TRPA1 ion channel	Liuqiong Gu	444	Drug Discovery
445	A methanolic extract of propolis collected from the Australian native stingless bee, <i>Tetragonula carbonaria</i> , scavenges free radicals and inhibits 5-lipoxygenase activity in vitro	Karina Hamilton	445	Drug Discovery
446	Opioid inhibition of cAMP in an optimised cell based assay	Dilanthi Herath	446	Drug Discovery
447	Activity of a novel alpha-conotoxin LsIA, isolated from <i>Conus limpusi</i>	Marco Inserra	447	Drug Discovery
448	Assessment of two-pore channels in MDA-MB-231 breast cancer cells	Aisyah H Jahidin	448	Drug Discovery
449	TRPV4 channels in basal-like breast cancer cells	Siti Y N Jamaludin	449	Drug Discovery

Board number	Abstract title	Presenter	Paper reference	Session theme
450	Characterisation of the hybrid orthosteric/allosteric bitopic nature of TBPB at the M1 muscarinic ACh receptor	Peter Keov	222	Drug Discovery
451	A novel analytical approach reveals a distinct pattern of stimulus bias for an antipsychotic drug at the dopamine D2 receptor	Carmen Klein Herenbrink	451	Drug Discovery
452	Development of a real-time, fluorescence based assay of mu-opioid receptor mediated inhibition of adenylate cyclase activity in Chinese hamster ovary cells	Alisa Knapman	452	Drug Discovery
453	In vitro assessment of ligand-mediated μ -opioid receptor interaction with Gprotein and β -arrestin 2	Ai-Leen Lam	453	Drug Discovery
454	The role of the secretory pathway calcium ATPases (SPCAs) in breast cancer	Jane Lee	176	Drug Discovery
455	Taking advantage of kinetic data: an alternative approach to obtain affinity estimates from GPCR-mediated intracellular calcium mobilization	Lauren May	455	Drug Discovery
456	The efficacy of kappa-opioid receptor agonists in pain and inflammation	Michael Morgan	456	Drug Discovery
457	Anti-inflammatory kinase inhibitors attenuate invasiveness and chemoresistance of glioblastoma cells	Lenka Munoz	457	Drug Discovery
458	Structure-function analysis of orthosteric, allosteric and bitopic ligand binding at adenosine A1 receptors	Anh Thi Ngoc Nguyen	177	Drug Discovery
459	Assessing the cytotoxicity of natural products on squamous cell carcinoma and human keratinocyte cell lines	Thao Nguyen	459	Drug Discovery
460	Alteration of SKBR3 cancer cell proliferation by silencing specific calcium pumps, channels and channel modulators	Elena Pera	460	Drug Discovery
461	Immunohistochemical analysis of PMCA2 expression in normal and malignant human breast tissues	Amelia Peters	461	Drug Discovery
462	Prediction of the GAG-binding interactions of four-helical cytokines	Maryam Sherkat Masoum	462	Drug Discovery
463	Calcium dependent regulation of multidrug resistance-associated protein 3 (MRP3/ABCC3) gene expression in a model of epithelial-mesenchymal transition (EMT)	Teneale Stewart	220	Drug Discovery
464	Investigating the mechanism of RXFP1 activation	Brad Hoare	464	Drug Discovery
503	Kavalactones: Novel positive modulators of $\alpha 1\beta 2/3\gamma 2L$ GABAA receptors	Emilie Christensen	503	Neuro- and Behavioural Pharmacology
504	Rat model of varicella zoster virus (VZV) induced neuropathic pain	Vaskar Das	504	Neuro- and Behavioural Pharmacology
505	Balb/c, C57BL/6J and CBA mice: characterisation of a new population of MDMA (ecstasy) users	Jake Gordon	505	Neuro- and Behavioural Pharmacology
506	Stress-reducing effect of GABA-enriched tea in humans: assessment of stress using heart rate variability	Tina Hinton	506	Neuro- and Behavioural Pharmacology
507	Attenuation of Toll-like receptor 4 reduces reward-like behaviours in mice	Jonathan Henry Jacobsen	170	Neuro- and Behavioural Pharmacology
508	Medication overuse headache is a manifestation of opioid induced hyperalgesia: A neuroimmune hypothesis and novel approach to treatment	Jacinta Johnson	508	Neuro- and Behavioural Pharmacology
509	Cannabinoid receptor interacting protein (CRIP1a) modulates CB1 receptor mediated GIRK channel activation in AtT-20 cells	Nilushi Karunaratne	509	Neuro- and Behavioural Pharmacology
510	Mechanical hyperalgesia, but not allodynia, is sustained through $\alpha 9$ -nicotinic ACh-receptor activity	Sarasa Mohammadi	510	Neuro- and Behavioural Pharmacology
511	Omega-conotoxins CVID and CVIE and two analogues display age-sensitive differences in biophysical properties in sensory neurons	Swetha Murali	511	Neuro- and Behavioural Pharmacology
512	Analgesic efficacy and mode of action of a small molecule angiotensin type 2 receptor antagonist in a rat model of prostate cancer induced bone pain	Arjun Muralidharan	169	Neuro- and Behavioural Pharmacology
513	TLR2/4KO mice do not display classical opioid receptor binding	Jacob Thomas	513	Neuro- and Behavioural Pharmacology
514	Ciguatoxin-induced cold allodynia is an acquired peripheral channelopathy involving preferential activation of TRPA1-expressing nociceptors	Irina Vetter	514	Neuro- and Behavioural Pharmacology
515	The influence of surgery-induced inflammation and isoflurane anaesthesia on postoperative cognitive outcome	Catherine Wood	515	Neuro- and Behavioural Pharmacology
531	Combinational therapy with oxycodone and zoledronic acid in inflammatory arthritis: The role of cytokines in acute and chronic inflammation	Waltraud Binder	531	Inflammation/Respiratory
532	Small airway reactivity to constrictors is differentially altered by chronic and acute inflammatory stimuli	Chantal Donovan	221	Inflammation/Respiratory
533	Choice of contractile agonist influences dilator efficacy in small airways in mouse lung slices	Meaghan FitzPatrick	533	Inflammation/Respiratory
534	Effect of anti-oxidants on influenza A infection in cigarette smoke-exposed mice	Prasanthi Gunasinghe	534	Inflammation/Respiratory
535	Investigating the role of PTEN in airway epithelial inflammation and remodelling in Chronic Obstructive Pulmonary Disease (COPD)	Amanda Vannitamby	535	Inflammation/Respiratory
550	Parents' perspectives about factors influencing adherence to pharmacotherapy for attention-deficit hyperactivity disorder (ADHD)	Rana Ahmed	550	Pharmacy Practice
551	Utilization of antihypertensive medication in elderly hospitalized patients	Tariq Alhawassi	551	Pharmacy Practice
552	Using academic detailing to support nurses' knowledge and confidence around antipsychotic drugs in dementia	Beate Kristine Antonsen	552	Pharmacy Practice
553	Interprofessional learning: impact on collaboration and attitudes towards health care teams	Sinthia Bosnic-Anticevich	553	Pharmacy Practice
554	Perceived barriers to pharmaceutical services by clients with mobility, vision and hearing disabilities	Victor Chuang	554	Pharmacy Practice
555	ASCI Anaphylaxis Training for Pharmacists	Rhonda Clifford	555	Pharmacy Practice
556	Risk factors for chlamydia: A survey of pharmacy-based emergency contraception consumers in Australia	Rhonda Clifford	556	Pharmacy Practice
557	Off-label and unlicensed prescribing in a Western Australian paediatric population	Petra Czarniak	557	Pharmacy Practice
558	Medines and their management among the older-aged living independently in leasehold retirement villages	Sheila Doggrell	558	Pharmacy Practice
559	The role of a medication incident reporting system in monitoring and signalling medication safety risks in primary care	Khaled Eddie	559	Pharmacy Practice
560	The perceived efficacy of non-prescription medications used by women who experience PMS	Kwang Choon Yee	560	Pharmacy Practice

Board number	Abstract title	Presenter	Paper reference	Session theme
561	Identification of Medication Errors amongst healthcare providers and academics in Denpasar Bali	Desak Ernawati	561	Pharmacy Practice
562	Assessment of chronic pain in the community	Joy Spark	562	Pharmacy Practice
563	A taste of your own medicine: prevalence of symptoms and self-medication in the community	James Green	563	Pharmacy Practice
564	The effect of weak English skills on academic performance, and the effectiveness of English language screening and remedial help for pharmacy students	James Green	564	Pharmacy Practice
565	The impact of the rescheduling of combination analgesics containing codeine on the practice of pharmacists	Joy Spark	565	Pharmacy Practice
566	Commercial influences on community pharmacist recommendations - impact of the Extended and Accelerated Price Disclosure	Lillian Huang	566	Pharmacy Practice
567	Concomitant use of alcohol and sedative-hypnotics in middle and older aged people: a systematic review	Simon Bell	567	Pharmacy Practice
568	The Medwise Model - is it working in the Bay of Plenty?	Maree Jensen	568	Pharmacy Practice
569	Timing of the drug administration in clinical practice in Australia	Gagandeep Kaur	569	Pharmacy Practice
570	Current tapering recommendations for discontinuing psychotropic medications: a systematic review	Greg Kyle	570	Pharmacy Practice
571	Creating a smoke free University of Canberra	Greg Kyle	571	Pharmacy Practice
572	Development of health professional relationships in an Interprofessional Learning workshop	Sofia Mavritsakis	572	Pharmacy Practice
573	"I just have to get off my arse" Barriers to medication adherence in young adults with chronic disease	Cobie McQueen	573	Pharmacy Practice
574	Community pharmacy-consumer/carer relationships are key in mental health care	Amary Mey	574	Pharmacy Practice
575	Utilization of actigraphy to assess undiagnosed sleep disturbances among healthy adults in home-based settings	Zaswiza Mohamad Noor	575	Pharmacy Practice
576	Investigating pharmacists interventions on discharge from hospital	Rayan Nahas	576	Pharmacy Practice
577	Developing a methodology to target and individualise interventions to improve medication adherence in community pharmacies	Thi-My-Uyen Nguyen	577	Pharmacy Practice
578	What are validated adherence scales really measuring?: A systematic review	Thi-My-Uyen Nguyen	578	Pharmacy Practice
579	Community pharmacists' awareness of secondary prevention of cardiovascular disease: a preliminary study	Hanni Puspitasari	579	Pharmacy Practice
580	Career perspectives of final year Australian pharmacy students	Grace Shen	580	Pharmacy Practice
581	The use of herbal medicines in lactation among breastfeeding women in Western Australia: A population-based survey	Tin Fei Sim	581	Pharmacy Practice
582	Accessibility of compounded progesterone products	Joy Spark	582	Pharmacy Practice
583	Medicines prices to patients in Australia	Loc Thai	583	Pharmacy Practice
584	Medicine information accompanying OTC medicines: Do labels and leaflets adequately support safe and appropriate use?	Vivien Tong	584	Pharmacy Practice
585	Usage of heart failure medications in frail and robust older inpatients	Kristina Waddell	585	Pharmacy Practice
586	Retrospective review of initial management of febrile neutropenia at Flinders Medical Centre: time to first dose of antibiotic therapy and risk stratification	Diane Watson	586	Pharmacy Practice
587	A longitudinal study of constipation and laxative use in a community-dwelling elderly population	Barry Werth	587	Pharmacy Practice
588	The impact of a pharmacist-led educational program on the psychotropic medication knowledge of aged care nurses	Juanita Westbury	588	Pharmacy Practice
589	Investigation of benzodiazepine utilisation in older people admitted to secondary care	Jackson Crawn	589	Pharmacy Practice
590	An audit of antibiotic prescribing for urinary tract infections in palliative care hospices in Scotland	Barbara Wimmer	590	Pharmacy Practice
591	A systematic review of healthcare interventions for asthma management during pregnancy	Elida Zairina	591	Pharmacy Practice
615	Genetic polymorphisms of the CNS immune and opioid signalling pathways are associated with morphine requirements after caesarean delivery	Daniel Barratt	615	Pharmacogenomics
616	The pharmacogenomics knowledge, education, practice and attitudes of hospital pharmacists in Adelaide, South Australia	Mafalda Dias	616	Pharmacogenomics
617	A pharmacogenomic study investigating outcomes in advanced non-small cell lung cancer patients receiving paclitaxel and carboplatin therapy with a focus on ethnic differences	Benjamin Harris	617	Pharmacogenomics
618	Impact of recipient and donor multidrug resistance protein 2 genetic variability on mycophenolic acid pharmacokinetics following kidney transplantation	Zaipul Md Dom	618	Pharmacogenomics
632	Changes in vimentin distribution accompany acrolein toxicity in epithelial lung cells: Association with protein adduct distribution	Kimberley Burton	632	Toxicology
633	Acute acrolein exposure produces molecular, morphologic and functional changes in airway epithelium as investigated in a novel mouse perfused tracheal system	Esther Cheah	633	Toxicology
634	Expression of TLRs and GFAP in the rat intestine following chemotherapy for cancer and relationship to gut toxicity and central pain behaviour	Janet Collier	634	Toxicology
635	Safety and toxicity profile of fenugreek	Song Huan Eow	635	Toxicology
636	Structure toxicity studies of drugs implicated in immune mediated idiosyncratic hepatotoxicity	Samuel Ho	636	Toxicology
637	Mulga snake (Pseudechis australis) envenoming: a spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy -Australian Snakebite Project (ASP-18)	Christopher Johnston	637	Toxicology
638	Resveratrol does not protect against paracetamol-induced cell death in mouse primary hepatocytes	Alice Kane	638	Toxicology
639	The effect of ageing on paracetamol pharmacokinetics and toxicity	John Mach	120	Toxicology
640	Isolation and characterisation of a procoagulant serine proteinase from the venom of the Eyelash pit viper, Bothriechis schlegelii	Emily Maguire	640	Toxicology
641	The teratogenic effect of dofetilide during rat limb development and association with drug-induced bradycardia and hypoxia	Diana Oakes	641	Toxicology
642	Chronic low dose exposure to STX inhibits neurite outgrowth	Katie O'Neill	642	Toxicology
643	Intravenous Lipid Emulsion does not improve haemodynamics or survival and increases drug concentrations in a rodent model of oral amitriptyline poisoning	Danielle Perichon	643	Toxicology
644	In vitro assessment of chemical sensitisation potential using the human cellline activation test (h-CLAT)	Chin Lin Wong	644	Toxicology